CODX vs. POCI, PYPD, NMTC, COCH, TMDIF, DRIO, VVOS, OSRH, BDMD, and FEMY
Should you be buying Co-Diagnostics stock or one of its competitors? The main competitors of Co-Diagnostics include Precision Optics (POCI), PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), Envoy Medical (COCH), Titan Medical (TMDIF), DarioHealth (DRIO), Vivos Therapeutics (VVOS), OSR (OSRH), Baird Medical Investment (BDMD), and Femasys (FEMY). These companies are all part of the "medical equipment" industry.
Co-Diagnostics vs. Its Competitors
Co-Diagnostics (NASDAQ:CODX) and Precision Optics (NASDAQ:POCI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.
Precision Optics has a net margin of -32.84% compared to Co-Diagnostics' net margin of -1,025.45%. Precision Optics' return on equity of -54.03% beat Co-Diagnostics' return on equity.
Co-Diagnostics currently has a consensus price target of $5.50, suggesting a potential upside of 1,867.80%. Given Co-Diagnostics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Co-Diagnostics is more favorable than Precision Optics.
In the previous week, Co-Diagnostics had 3 more articles in the media than Precision Optics. MarketBeat recorded 3 mentions for Co-Diagnostics and 0 mentions for Precision Optics. Co-Diagnostics' average media sentiment score of 0.00 equaled Precision Optics'average media sentiment score.
15.0% of Co-Diagnostics shares are held by institutional investors. Comparatively, 13.7% of Precision Optics shares are held by institutional investors. 8.4% of Co-Diagnostics shares are held by company insiders. Comparatively, 13.0% of Precision Optics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Co-Diagnostics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Precision Optics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500.
Precision Optics has higher revenue and earnings than Co-Diagnostics. Precision Optics is trading at a lower price-to-earnings ratio than Co-Diagnostics, indicating that it is currently the more affordable of the two stocks.
Summary
Co-Diagnostics beats Precision Optics on 9 of the 16 factors compared between the two stocks.
Get Co-Diagnostics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CODX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CODX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Co-Diagnostics Competitors List
Related Companies and Tools
This page (NASDAQ:CODX) was last updated on 7/19/2025 by MarketBeat.com Staff
Free CODX Stock Alerts